---
schema_version: "secwatch.filing_event.v1"
accession: "0000947871-23-000948"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T11:25:03.548636+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# CVS Health elects Boston Scientific CEO Michael F. Mahoney to board

## Summary
- Michael F. Mahoney elected to CVS Health Board, effective November 1, 2023.
- Mahoney has been President and CEO of Boston Scientific (BSX) since 2012.
- Board determined Mahoney independent under NYSE and CVS guidelines.
- Compensation consistent with other non-employee directors, subject to proration.

## SEC filing metadata
- accession: 0000947871-23-000948
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000094787123000948/0000947871-23-000948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000094787123000948/ss2511976_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000947871-23-000948
- JSON: https://secwatch.observer/filing/0000947871-23-000948.json
- Plain text: https://secwatch.observer/filing/0000947871-23-000948.txt

## Key facts
- Executive change
  Michael F. Mahoney was elected as Director at CVS HEALTH Corp.
  - Action: elected
  - Role: Director
  source text: On September 20, 2023, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected Michael F. Mahoney to serve on the Board, effective November 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/64803/000094787123000948/0000947871-23-000948-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.